University of Cincinnati researcher secures $3.3M grant to study microplastics’ impact on heart
Grant and Award Announcement
Updates every hour. Last Updated: 16-Jun-2026 10:15 ET (16-Jun-2026 14:15 GMT/UTC)
The National Institute of Environmental Health Sciences has awarded a five-year, $3.3 million grant to a University of Cincinnati College of Medicine researcher to study the potential cardiovascular toxicity of microplastics and nanoplastics.
A phase 1 clinical trial testing the safety of a leishmaniasis vaccine is set to begin in the coming months – the first vaccine created to protect against the disfiguring skin disease common in tropical regions of the world and gaining ground in the United States. The researcher who led development of the vaccine is the senior author of a New England Journal of Medicine review article published last week describing the difficulties of treating most forms of the disease and reporting that the live vaccine, found to be safe in animals, is expected to be tested in humans later this year.
Rifampicin resistant tuberculosis is a major global health crisis. A new study shows that the most common rifampicin resistance mutation in tuberculosis rewires bacterial gene regulation in a way that creates specific metabolic vulnerabilities. The findings could guide the development of combination therapies designed not only to kill drug resistant tuberculosis, but to suppress drug resistance itself.
A combination of two widely available anti-rheumatic drugs offers the first effective and affordable treatment for patients with Sjögren’s disease with systemic disease activity, according to new results from a clinical trial that was coordinated by UMC Utrecht. The study showed that treatment with leflunomide and hydroxychloroquine reduced disease activity in patients with moderate-to-severe disease, while maintaining a favorable safety profile.